Do we need biomarkers for disc degeneration?
Disc degeneration plays a major role in this country's medical, social and economic structure. The life-time prevalence of low back pain, which has disc degeneration as its cause, is about 80% in the general population. It is a primary cause of disability and estimated costs related to low back disorders exceed $100 billion per year in the U.S. alone. Biomarkers are becoming increasingly important as indicators of the presence of disease, and in evaluating outcomes during clinical treatment. Cell-based biologic therapies which are currently being developed to treat disc degeneration are going to be most efficacious when applied to the early stages of disc disease. In this article we ask: 1) Whether there are existing biomarkers which could play a role in detecting early stages of disc degeneration, and 2) Highlight exciting potentials in future biomarker screening for disc degeneration.
Gruber
Helen E
HE
Department of Orthopaedic Surgery, Carolinas Medical Center, Charlotte, N.C.
Hanley
Edward N
EN
J Bone Joint Surg Am. 1999 May;81(5):716-30
10360702
Spine (Phila Pa 1976). 1990 May;15(5):411-5
2363069
Expert Opin Biol Ther. 2003 Dec;3(8):1209-14
14640946
Spine J. 2004 Jan-Feb;4(1):44-55
14749193
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:21-4
16595438
Spine J. 2006 Mar-Apr;6(2):120-4
16517381
Spine (Phila Pa 1976). 2002 Aug 1;27(15):1626-33
12163723
Clin Chem. 2006 Sep;52(9):1713-21
16858073
Neuroreport. 2000 Feb 7;11(2):279-81
10674470
Spine (Phila Pa 1976). 1999 Apr 15;24(8):742-6
10222523
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:95-8
16595452
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:72-5
16595448
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
11240971
Spine (Phila Pa 1976). 2001 Nov 1;26(21):2323-7
11679816
Eur Spine J. 2006 May;15(5):627-33
15990991
Arthritis Rheum. 2005 Jan;52(1):105-11
15641044
Clin Chem. 2006 Sep;52(9):1635-7
16940460